Optimization of a Novel Tissue Test to Visualize and Quantify Membrane PSMA Expression in Prostate Cancer

Presenters: Julie Bailis, Ph.D. | Director of Research, Inflammation/Oncology, Amgen

Hemi Dimant, Ph.D. | Director of Applications for Advanced Pathology Services, Invicro

 

Prostate-specific membrane antigen (PSMA) plays a pivotal role in prostate cancer tumorigenesis and is a key target for prostate cancer therapy. As such, it is important to assess membrane-PSMA expression to support the development of PSMA-targeting therapeutics, such as bispecific antibodies, which can recognize even low levels of target antigen. To that effort, we developed in collaboration with Amgen a Quanticell immunostaining assay to better detect and characterize PSMA expression in tissue sections in order to improve scoring of clinical samples.

During this webinar, the presenters will:

  1. Introduce Quanticell, a novel immunostaining detection technology
  2. Present study design to evaluate assay performance, including specificity, sensitivity, dynamic range and quantification
  3. Present cell line and clinical tissue results and the implications for future study designs
Tuesday, October 13
12:00pm EDT

Register for On-Demand Access:

105-1051774_female-head-silhouette-grey-hd-png-download

JULIE BAILIS, PH.D.

Director of Research, Inflammation/Oncology, Amgen

Dr. Bailis is in Discovery Research at Amgen, where her group is focused on the discovery and development of new therapies for solid tumors, including bispecific T cell engager (BiTE) molecules. Previous to her work at Amgen, Dr. Bailis was a Damon Runyon Fellow at the Salk Institute for Biological Studies. She received her Ph.D. from Yale University.

Dimant_Hemi

HEMI DIMANT, PH.D.

Director of Applications for Advanced Pathology Services, Invicro

Dr. Dimant currently serves as the Director of Applications for Invicro's Advanced Pathology Services. In his role, he works closely with sponsors to design preclinical research studies, provide scientific guidance, and data interpretation. Leading Invicro’s CFT contract research services, Dr. Dimant is responsible for the development and implementation of new applications across various disease areas. Dr. Dimant holds a Ph.D. in Biotechnology from Tel Aviv University, with a focus in neuroscience. With his extensive experience developing and applying fluorescent and optical tissue imaging techniques, he has held several R&D roles within the biotechnology space. At Third Rock Ventures, Dr. Dimant was a founding team member of Voyager Therapeutics.